About Zinc finger protein 3 homolog
Zinc finger protein 3 homolog (ZFP3) is a protein
from Homo sapiens identified by UniProt accession
Q96NJ6, 502 residues long.
MolForge cross-references it against 0 known binders and
19 disease associations.
Target properties
| Protein name | Zinc finger protein 3 homolog |
| UniProt accession | Q96NJ6 |
| Gene | ZFP3 |
| Organism | Homo sapiens |
| Length | 502 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (19)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.30
- family history of Alzheimer’s disease · score 0.22
- lymphocyte count · score 0.18
- late-onset Alzheimers disease · score 0.08
- Alzheimer disease · score 0.03
- mean platelet volume · score 0.02
- Down syndrome · score 0.02
- body height · score 0.02
- platelet component distribution width · score 0.02
- hematocrit · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96NJ6-F1 | alphafold | PREDICTED | 74.44 | — |
Amino-acid sequence (502 residues)
MGTENKEVIP KEEISEESEP HGSLLEKFPK VVYQGHEFGA GCEEDMLEGH SRESMEEVIE QMSPQERDFP SGLMIFKKSP SSEKDRENNE SERGCSPSPN LVTHQGDTTE GVSAFATSGQ NFLEILESNK TQRSSVGEKP HTCKECGKAF NQNSHLIQHM RVHSGEKPFE CKECGKTFGT NSSLRRHLRI HAGEKPFACN ECGKAFIQSS HLIHHHRIHT GERPYKCEEC GKAFSQNSAL ILHQRIHTGE KPYECNECGK TFRVSSQLIQ HQRIHTEERY HECNECGKAF KHSSGLIRHQ KIHTGEKPYL CNECGKGFGQ SSELIRHQRI HTGDKPYECN ECGKTFGQNS EIIRHIRIHT GEKPYVCKEC GKAFRGNSEL LRHERIHTGE KPYECFECGK AFRRTSHLIV HQRIHTGEKP HQCNECARTF WDNSELLLHQ KIHIGEKPYE CSECEKTFSQ HSQLIIHQRI HTGEKPYECQ ECQKTFSRSS HLLRHQSVHC ME
Explore Zinc finger protein 3 homolog with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets